Elisa Montechiarello Selected Research

Splenectomy

1/2015

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisa Montechiarello Research Topics

Disease

1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2017
1	Disease Progression 01/2015
1	Sepsis (Septicemia) 01/2015
1	Pneumonia (Pneumonitis) 01/2015
1	Lymphoma (Lymphomas) 01/2015
1	Neoplasms (Cancer) 01/2015

Drug/Important Bio-Agent (IBA)

2	Rituximab (Mabthera)FDA Link 01/2017 - 01/2015
1	Bendamustine Hydrochloride FDA Link 01/2017
1	Lenalidomide (CC 5013)FDA Link 01/2017
1	liposomal doxorubicin (Doxil)FDA Link 01/2015
1	Prednisone (Sone)FDA LinkGeneric 01/2015
1	Vincristine (Oncovin)FDA LinkGeneric 01/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2015

Therapy/Procedure

1	Splenectomy 01/2015